We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.50 | 1.85% | 27.475 | 27.375 | 27.57 | 27.61 | 26.94 | 26.945 | 404,068 | 22:50:04 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Merck & Co. (MRK) on Monday said vericiguat, an investigational drug it is developing with Bayer AG (BAYN.XE), met the primary efficacy endpoint in a phase 3 study in patients with worsening chronic heart failure.
The Kenilworth, N.J., drug maker said vericiguat reduced the risk of the composite endpoint of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction compared to placebo when given in combination with available heart failure therapies.
Merck and Germany's Bayer formed a worldwide collaboration in October 2014 in the field of soluble guanylate cyclase modulators such as vericiguat.
Merck said the companies will present the study results at an upcoming medical meeting in 2020.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 18, 2019 06:59 ET (11:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
